FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3 study with abelacimab initiated by Anthos Therapeutics Abelacimab is a dual-acting, […]
Tag: AFib
Acutus Medical Announces Acceptance of the AcQForce Flutter Abstract for Presentation during the Late-Breaking Clinical Trials and First Report Investigations sessions at the 2023 AF Symposium
CARLSBAD, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the acceptance of the AcQForce Flutter abstract titled “AcQForce […]
Successful First-in-Human Clinical Study of Kardium’s Next Generation Globe® Pulsed Field System
VANCOUVER, British Columbia–(BUSINESS WIRE)–Kardium Inc. announces the successful first-in-human study of its next generation Globe® Pulsed Field System to treat atrial fibrillation (AF) using pulsed field ablation (PFA) therapy. Working with Dr. Vivek Reddy1 from Mount Sinai Hospital (New York, USA), and […]
AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients
Primary endpoint was not met for the modified intent-to-treat (mITT) population; however, clinical benefit observed in coronary artery bypass graft (CABG) patients Data showed relative risk reduction in specific study populations and overall lower rates of rehospitalization within 30 days […]
Volta Medical’s AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication
Volta VX1 decision support software reproduces expert-physician electrogram (EGM) analysis that can assist physicians in the real-time identification of specific abnormal electrograms in a persistent atrial fibrillation (AF) population After a one-year follow-up, patients demonstrated a high freedom from atrial […]
CardioFocus Announces Pulsed Field Ablation Milestones
MARLBOROUGH, Mass., July 19, 2022 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (Afib), today announced several milestones toward the development of a next generation pulse field ablation (PFA) technology for treatment of AFib, […]
Study Demonstrates Cardiologs’ AI Can Predict Occurrence of Atrial Fibrillation in the Near Future
Newly published research shows that Cardiologs’ deep learning model can predict the short-term risk of atrial fibrillation (AFib) based on 24-hour Holter recordings that show normal sinus rhythm. PARIS and BOSTON, June 21, 2022 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) cardiology […]
AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial
Trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy™ Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial […]
Kardium’s Globe® System Begins Clinical Trial at St. Paul’s Hospital
A revolutionary device that treats Atrial Fibrillation (AF) – the world’s most common heart rhythm disorder – helps support the healthy aging of BC’s population. April 12, 2022, 9:00 AM Pacific Daylight Time | VANCOUVER, British Columbia – Kardium Inc. announces a successful […]
Zio® by iRhythm Shown to Prevent Hospital Admissions, Aid in Early Detection of AF
New clinical research presented at ACC.22 shows that the Zio service is a viable solution for the early detection of silent atrial fibrillation Additional data shows that Zio AT can positively impact hospital resources – saving one healthcare system 136 inpatient […]